This page contains a Flash digital edition of a book.
RESEARCH ROUND-UP |


research round-up


EVALUATION OF A LONG PULSED 1064-NM ND:YAG LASER FOR IMPROVEMENT IN APPEARANCE OF CELLULITE


Truitt A, Elkeeb L, Ortiz A, Saedi N, Echague A, Kelly KM. J Cosmet Laser Ther 2012; 14(3): 139–44


Objectives: The objective of this investigation was to evaluate safety and effectiveness of a long-pulsed 1064 Nd:YAG laser as a method for improvement in cellulite appearance and to evaluate parameter selection. Materials and methods: Twenty-two female subjects with posterior leg cellulite were randomly assigned to treatment of left or right thigh with higher


C


ELLULITE IS A COMMON, UNWANTED condition, which is challenging to treat.


energy treatment with cryogen spray cooling (CSC) (10-mm spot size; 50 J/cm2


duration and CSC settings of 30-ms duration with a 20-ms delay) or lower energy treatment with no CSC (10 mm; 20 J/cm2


; 50 ms). Subjects


received three treatments at 4 weeks intervals. Digital photographs and circumference measurements were taken pre-treatment and up to 6 months post-treatment. Results: Nineteen subjects completed three treatments and 16 subjects completed 6-month follow-up. Circumference measurements pre- and post-treatment were not significantly different. Blinded evaluators noted mild improvement in three of seven subjects in high energy group and moderate improvement in two of nine subjects in low energy group. Conclusion: Multiple passes with a long-pulsed 1064 Nd:YAG achieved mild or moderate improvement in some subjects as rated by blinded evaluators.


AMYLOID BETA (Aβ) PEPTIDE MODULATORS AND OTHER CURRENT TREATMENT STRATEGIES FOR ALZHEIMER’S DISEASE (AD)


Lukiw WJ. Expert Opin Emerg Drugs 2012; 17(1): 43–60


disorder whose incidence is reaching epidemic proportions. The prevailing


A 54 ❚


Ôamyloid cascade hypothesisÕ, which maintains that the aberrant proteolysis of beta-amyloid precursor protein (βAPP) into neurotoxic amyloid beta (Aβ) peptides is central to the etiopathology of AD, continues to dominate pharmacological approaches to


June 2012 | prime-journal.com LZHEIMERÕS DISEASE (AD) IS A common, progressive neurological ; 50-ms pulse


A round-up of the most recently published academic articles and research


the clinical management of this insidious disorder. This review is a compilation and update on current pharmacological strategies designed to down-regulate Aβ42 peptide generation in an effort to ameliorate the tragedy of AD. Areas covered: This review utilized online data searches at various open online-access websites including the Alzheimer Association, Alzheimer Research Forum; individual drug company databases; the National Institutes of Health (NIH) Medline; Pharmaprojects database; Scopus; inter-University research communications; and unpublished research data. Expert opinion:


Anti-acetylcholinesterase-,


chelation-, N-methyl-D-aspartate (NMDA) receptor antagonist-, statin-, immunization-, β-secretase-,


Aβ γ-secretase-


based, and other strategies to modulate βAPP processing, have dominated pharmacological approaches directed against AD-type neurodegenerative pathology. Cumulative clinical results of these efforts remain extremely disappointing, and have had little overall impact on the clinical management of AD. While a number of novel approaches are in consideration and development, to date there is still no effective treatment or cure for this expanding healthcare concern.


PERSONALIZING DERMATOLOGY: THE FUTURE OF GENOMIC EXPRESSION PROFILING TO INDIVIDUALIZE DERMATOLOGIC THERAPY


Rizzo AE, Maibach HI. J Dermatolog Treat 2012; 23(3): 161–7


A


T THE START OF THE 21ST CENTURY, the human genome project provided the


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84